ZENJI PHARMACEUTICALS (SUZHOU) LTD

Overview

ZENJI PHARMACEUTICALS (SUZHOU) LTD is an active pharmaceutical ingredient (API) supplier with 10 active FDA Type II Drug Master Files, covering ALECTINIB INTERMEDIATE(CAS NUMBER:1256584-75-4); DAPAGLIFLOZIN; ERIBULIN FRAGMENT A; ERIBULIN FRAGMENT C14-C26; ERIBULIN INTERMEDIATE N-5; ERIBULIN INTERMEDIATE N-6.

API / Drug Master Files

ZENJI PHARMACEUTICALS (SUZHOU) LTD holds 10 active (10 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• ALECTINIB INTERMEDIATE(CAS NUMBER:1256584-75-4)Active2026-03-19
• LANTHANUM CARBONATEActive2025-11-25
• DAPAGLIFLOZINActive2025-05-20
• FINERENONEActive2024-09-28
• ERIBULIN FRAGMENT C14-C26Active2024-08-29
• ERIBULIN MESYLATEActive2023-12-26
• LANTHANUM CARBONATEActive2023-03-15
• ERIBULIN INTERMEDIATE N-5Active2023-01-05
• ERIBULIN FRAGMENT AActive2022-04-29
• ERIBULIN INTERMEDIATE N-6Active2021-12-31

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to ZENJI PHARMACEUTICALS (SUZHOU) LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.